All Clinical Trials

Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us

Terms of use Privacy policy

All Clinical Trials 2026All Rights reservedPrivacy Policy Terms of Use

Locations Texas Arizona California New York Massachusetts Florida New Jersey Utah All locationsConditions Oncology Alzheimer's Diabetes Multiple Sclerosis Arthritis Hepatitis C COPD Depression All conditionsTreatments Weight Loss Stem Cells Vaccines Sleep Apnea Medical Devices IVF Dental Drug Addiction All treatmentsInstitutions Pfizer Moderna NIH UCLA Stanford M.D. Anderson Labcorp All institutionsResourcesBlog FAQ Medical advisors

Terms of use Privacy policy

All Clinical Trials 2026All Rights reservedPrivacy Policy Terms of Use

Clinical trials
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Apply

Pembrolizumab, Bevacizumab, CyclophosphamidePhase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Basic information

Step 1/5

Provide your basic information

Age

ZIP code